BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Sarepta Therapeutics (Formerly known as AVI BioPharma, Inc.) 

245 First Street
Suite 1800
Cambridge  Massachusetts  02142  U.S.A.
Phone: 503-227-0554 Fax: 503-227-0751


SEARCH JOBS

View Clinical Trials from BioPharm Insight



Industry
Biotechnology






 Company News
Sarepta (SRPT) Announces Fourth Quarter And Full-Year 2014 Financial Results And Recent Corporate Developments 2/26/2015 11:43:19 AM
Sarepta (SRPT) To Present Company Overview At Upcoming Conferences 2/24/2015 11:10:19 AM
Sarepta (SRPT) To Announce Fourth Quarter And Full-Year 2014 Financial Results And Corporate Update On February 26, 2015 2/19/2015 12:31:10 PM
Despite CEO's Comments, Experimental Sarepta (SRPT) Drug Protects Lab Monkeys From Ebola 2/11/2015 6:21:58 AM
BIOCEO15: Sarepta (SRPT) CEO Feels Backlash After Saying Ebola Research Isn’t in "Shareholder Interest" 2/9/2015 11:36:10 AM
Sarepta (SRPT) To Present Company Overview At Upcoming Conferences 2/4/2015 10:40:27 AM
BioMarin (BMRN), Sarepta (SRPT) Rivalry Gets Nasty in Battle Over Data 1/19/2015 6:07:38 AM
Sarepta (SRPT) Announces First Patient Dosed In European Phase1/2 Study Of SRP-4053 In Duchenne Muscular Dystrophy Patients 1/14/2015 7:56:48 AM
Breaking: J.P. Morgan: BioMarin (BMRN) Takes Shot at Sarepta (SRPT), Says DMD Drug Has Better Results So Far 1/12/2015 5:12:05 PM
Sarepta Therapeutics (SRPT) Reports Long-Term Outcomes Through 168 Weeks From Phase 2b Study Of Eteplirsen In Duchenne Muscular Dystrophy 1/12/2015 12:10:20 PM
12345678910...